PORTOLA VALLEY, Calif., May 11 Spectros, developer and manufacturer of advanced molecular sensing and imaging devices which shed light on life-threatening diseases, presented 4 papers at the annual PAS conference held in Vancouver, B.C. May 1-4, 2010. The presented papers confirm the value added when using the T-Stat VLS tissue oximeter in neonates and infants for the detection of ischemia. The noninvasive white LED sensors provide a gentle way of monitoring, which is sensitive to this very delicate patient population.
"The abstracts and posters presented at PAS show a level of commitment from leading institutions and their support of the T-Stat in the critical care setting," comments Robert Kum, Director of Commercial Development. "Medical professionals depend on the T-Stat VLS Tissue Oximeter to get a clear view of tissue saturation, which enables them to make timely, more informed patient care decisions."
Duke University in Durham, NC put together a study on red blood cell transfusions and mesenteric perfusion in preterm infants. The Pediatrics and Neonatology department at Georgetown University Hospital in Washington, DC presented the validation of visible light tissue oximetry in newborn infants. Noninvasive measurement of local tissue perfusion and its correlation with hemodynamic indices during transition in term infants was completed by The Children's Hospital at OU Medical Center in Oklahoma City, OK and postoperative differences in regional tissue oxygenation and fractional oxygen extraction (FTOE) in newborn infants with hypoplastic left heart syndrome (HLHS) and transposition of great arteries (TGA) was conducted at Columbia University in New York, NY.
"These studies have helped to define normal tissue oxygen extraction in newborn infants, for term, pre-term and congenital heart defect patients (hypoplastic left heart syndrome and transposition of the great arteries)," said Michael Fierro, Director of Research and Development. "These studies form the foundation for the work that Spectros and clinicians are currently exploring to define the clinical benefit of having an absolute, accurate, and reliable measure of tissue oxygen saturation in the newborn patient population."
Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology. The noninvasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, allowing for earlier diagnosis and lower costs. Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only. T-Stat and Continuum are trademarks of the Spectros Corporation.)
For further information, visit www.spectros.com